Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRA2A C-1291G polymorphism and dexmedetomidine response during lower limb surgery
ChiCTR1800020255Phase 4Recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine in procedural sedation and analgesia (PSA), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: ADRA2A C-1291G genotyping, Bispectral Index value and 6 more. Started Jan 2019; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
procedural sedation and analgesia (PSA)
Beyond the preview
Go deeper on ChiCTR1800020255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020255.